With Acquisition done, Pathwork Diagnostics Affirms Intent to Seek FDA Clearance This Year | GenomeWeb

Despite Predicant Biosciences' acquisition of Pathwork Informatics last week, the combined new firm, to be called Pathwork Diagnostics, will stay true Pathwork's original plan to launch a test for the origin of secondary and unspecified malignant cancers by year end, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.